Literature DB >> 11724759

Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.

S Talon1, A De Luca, M De Bellis, J F Desaphy, G Lentini, A Scilimati, F Corbo, C Franchini, P Tortorella, H Jockusch, D Conte Camerino.   

Abstract

1. Searching for the structural requirements improving the potency and the stereoselectivity of Na(+) channel blockers as antimyotonic agents, new derivatives of tocainide, in which the chiral carbon atom is constrained in a rigid alpha-proline or pyrrolo-imidazolic cycle, were synthesized as pure enantiomers. 2. Their ability to block Na(+) currents, elicited from -100 to -20 mV at 0.3 Hz (tonic block) and 2-10 Hz (use-dependent block) frequencies, was investigated in vitro on single fibres of frog semitendinosus muscle using the vaseline-gap voltage-clamp method. 3. The alpha-proline derivative, To5, was 5 and 21 fold more potent than tocainide in producing tonic and 10 Hz-use-dependent block, respectively. Compared to To5, the presence of one methyl group on the aminic (To6) or amidic (To7) nitrogen atom decreased use-dependence by 2- and 6-times, respectively. When methylene moieties were present on both nitrogen atoms (To8), both tonic and use-dependent block were reduced. 4. Contrarily to tocainide, all proline derivatives were stereoselective in relation to an increased rigidity. A further increase in the molecular rigidity as in pyrrolo-imidazolic derivatives markedly decreased the drug potency with respect to tocainide. 5. Antimyotonic activity, evaluated as the shortening of the time of righting reflexes of myotonic adr/adr mice upon acute drug in vivo administration was 3 fold more effective for R-To5 than for R-Tocainide. 6. Thus, constraining the chiral centre of tocainide in alpha-proline cycle leads to more potent and stereoselective use-dependent Na(+) channel blockers with improved therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724759      PMCID: PMC1573071          DOI: 10.1038/sj.bjp.0704366

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  An improved vaseline gap voltage clamp for skeletal muscle fibers.

Authors:  B Hille; D T Campbell
Journal:  J Gen Physiol       Date:  1976-03       Impact factor: 4.086

2.  Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na(+) channels with increased potency and improved use-dependent activity.

Authors:  C Franchini; F Corbo; G Lentini; G Bruno; A Scilimati; V Tortorella; D Conte Camerino; A De Luca
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

3.  Stereoselective interaction of tocainide and its chiral analogs with the sodium channels in human myoballs.

Authors:  D Tricarico; B Fakler; W Spittelmeister; J P Ruppersberg; R Stützel; C Franchini; V Tortorella; D Conte-Camerino; R Rüdel
Journal:  Pflugers Arch       Date:  1991-04       Impact factor: 3.657

Review 4.  Molecular pathophysiology of voltage-gated ion channels.

Authors:  F Lehmann-Horn; R Rüdel
Journal:  Rev Physiol Biochem Pharmacol       Date:  1996       Impact factor: 5.545

5.  Successful treatment with tocainide of recessive generalized congenital myotonia.

Authors:  E W Streib
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

Review 6.  Drug therapy. Tocainide.

Authors:  D M Roden; R L Woosley
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

7.  The different use dependences of tocainide and benzocaine are correlated with different effects on sodium channel inactivation.

Authors:  A DeLuca; T Pröbstle; H Brinkmeier; R Rüdel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

8.  Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.

Authors:  A De Luca; F Natuzzi; J F Desaphy; G Loni; G Lentini; C Franchini; V Tortorella; D C Camerino
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

9.  Point mutations at N434 in D1-S6 of mu1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers.

Authors:  C Nau; S Y Wang; G R Strichartz; G K Wang
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

10.  Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.

Authors:  J F Desaphy; D Conte Camerino; C Franchini; G Lentini; V Tortorella; A De Luca
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

View more
  7 in total

1.  Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.

Authors:  Gualtiero Milani; Maria Maddalena Cavalluzzi; Concetta Altamura; Antonella Santoro; Mariagrazia Perrone; Marilena Muraglia; Nicola Antonio Colabufo; Filomena Corbo; Elisabetta Casalino; Carlo Franchini; Isabella Pisano; Jean-François Desaphy; Antonio Carrieri; Alessia Carocci; Giovanni Lentini
Journal:  ChemMedChem       Date:  2021-10-05       Impact factor: 3.540

2.  Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Authors:  Annamaria De Luca; Sophie Talon; Michela De Bellis; Jean-François Desaphy; Carlo Franchini; Giovanni Lentini; Alessia Catalano; Filomena Corbo; Vincenzo Tortorella; Diana Conte-Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

3.  Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.

Authors:  Annamaria De Luca; Michela De Bellis; Filomena Corbo; Carlo Franchini; Marilena Muraglia; Alessia Catalano; Alessia Carocci; Diana Conte Camerino
Journal:  Neuromuscul Disord       Date:  2011-07-29       Impact factor: 4.296

4.  Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Authors:  Michela De Bellis; Annamaria De Luca; Jean F Desaphy; Roberta Carbonara; Judith A Heiny; Ann Kennedy; Alessia Carocci; Maria M Cavalluzzi; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Biophys J       Date:  2013-01-22       Impact factor: 4.033

Review 5.  Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Authors:  Paola Imbrici; Antonella Liantonio; Giulia M Camerino; Michela De Bellis; Claudia Camerino; Antonietta Mele; Arcangela Giustino; Sabata Pierno; Annamaria De Luca; Domenico Tricarico; Jean-Francois Desaphy; Diana Conte
Journal:  Front Pharmacol       Date:  2016-05-10       Impact factor: 5.810

6.  Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

Authors:  Michela De Bellis; Roberta Carbonara; Julien Roussel; Alessandro Farinato; Ada Massari; Sabata Pierno; Marilena Muraglia; Filomena Corbo; Carlo Franchini; Maria Rosaria Carratù; Annamaria De Luca; Diana Conte Camerino; Jean-François Desaphy
Journal:  Neuropharmacology       Date:  2016-10-13       Impact factor: 5.250

7.  Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.

Authors:  Michela De Bellis; Francesca Sanarica; Alessia Carocci; Giovanni Lentini; Sabata Pierno; Jean-François Rolland; Diana Conte Camerino; Annamaria De Luca
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.